Open-label, Uncontrolled Postmarketing Study to Evaluate Immunogenicity, Safety and Tolerability of Cell-derived A/H1N1 Influenza HA Vaccine in Healthy Japanese Elderly Subjects.
Phase of Trial: Phase IV
Latest Information Update: 30 May 2016
At a glance
- Drugs Influenza A virus vaccine-H1N1; MF 59
- Indications Influenza A virus H1N1 subtype
- Focus Pharmacodynamics
- Sponsors Novartis
- 04 Jan 2012 Official title amended as reported by ClinicalTrials.gov.
- 06 Aug 2010 Trial location (Japan) added as reported by ClinicalTrials.gov.
- 06 Aug 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.